Key facts
- Bioio’s last known valuation is $10.0M (Feb 2024).
- It has raised $3.0M; the latest was Later Stage VC in Mar 2025.
- Notable investors include BioGenerator Ventures, Missouri Technology Corporation, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, quadraScope Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Bioio
- ·The full record, as it builds
Funding rounds
No funding rounds for Bioio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bioio
Developer of the mechanism of action technologies(MOAT) platform designed to study how a chemical or drug produces a biological effect. The company's platform uses focused ultrasound to ensure the drug efficacy and the reason behind the failure of therapies, enabling clients to focus on identifying drugs precisely targeting specific proteins.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2019
- Employees
- 3
- Website
- bioio.tech/
- Ownership
- Privately Held (backing)
Bioio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bioio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bioio in its N-PORT filings yet. We sweep new filings monthly.